Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype.

The American journal of pathology - 1 Nov 1997

Ortéga N, Jonca F, Vincent S, Favard C, Ruchoux M M, Plouët J

Abstract excerpt

The hypothesis that tumor growth is angiogenesis dependent has been documented by a considerable body of direct and indirect experimental data. A prerequisite for the development of novel anti-angiogenic agents is the design of drugs that would be active only on those endothelial cells with an angiogenic phenotype. We took advantage of the anti-idiotypic strategy to obtain circulating agonists specific for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Cell Division

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Movement

Share to Immunoglobulin G

Share to Ligands

Share to Mice, Nude

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 9358746
PMCID: PMC1858082

Genes

KDR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype.PMID 9358746Read ↗

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.Semantic proximity Read ↗

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transferSemantic proximity Read ↗

A novel vascular endothelial growth factor-trap KP-VR2 with enhanced ligand blockingSemantic proximity Read ↗

A high‐affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo‐vasculature <i>in vivo</i>Semantic proximity Read ↗

Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2.Semantic proximity Read ↗

An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype.Semantic proximity Read ↗

Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants.Semantic proximity Read ↗

Switch to the angiogenic phenotype during tumorigenesis.Semantic proximity Read ↗

Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.Semantic proximity Read ↗

Simultaneous, phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody enhances antiangiogenic effects in vivo.Semantic proximity Read ↗

Regression of Human Breast Carcinoma in Nude Mice After Ad <i>sflt</i> Gene Therapy is Mediated by Tumor Vascular Endothelial Cell ApoptosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.